Abstract | OBJECTIVE: METHODS: Sixty-two consecutive patients with unclear diagnosis at MDCT/ultrasound underwent dynamic CE-MRI of the kidneys with 0.05 mmol/kg gadobenate dimeglumine. Retrospective image evaluation was performed by two blinded readers. Lesion diagnosis at CE-MRI was correlated with findings from histology following tumor resection or from imaging follow-up after at least 1 year. Assessments were performed of diagnostic quality and level of diagnostic information. RESULTS: Thirty-nine (63 %) patients were correctly diagnosed with malignant lesions (36 with RCC, 2 with renal metastases, 1 with lymphoma) while 14 (22.6 %) patients were correctly diagnosed with benign (n = 12) or no (n = 2) lesions. Eight patients were considered false positive (5 with oncocytoma, 3 with atypical AML) and 1 patient false negative (atypical RCC). The sensitivity, specificity, accuracy, PPV, and NPV for the diagnosis of malignant renal lesions were 97.5 % (39/40), 63.6 % (14/22), 85.5 % (53/62), 83.0 % (39/47), and 93.3 % (14/15), respectively. Images were excellent in 60 and good in 2 patients. Minimal artifacts that did not compromise diagnosis were noted in 4/62 patients. CONCLUSION:
|
Authors | Guenther Schneider, Thorsten Probst, Miles A Kirchin, Jonas Stroeder, Peter Fries, Arno Buecker |
Journal | La Radiologia medica
(Radiol Med)
Vol. 120
Issue 12
Pg. 1100-11
(Dec 2015)
ISSN: 1826-6983 [Electronic] Italy |
PMID | 26088468
(Publication Type: Journal Article)
|
Chemical References |
- Contrast Media
- Organometallic Compounds
- gadobenic acid
- Meglumine
|
Topics |
- Adolescent
- Adult
- Aged
- Artifacts
- Carcinoma, Renal Cell
(diagnosis, pathology)
- Child
- Contrast Media
(administration & dosage)
- Diagnosis, Differential
- False Negative Reactions
- False Positive Reactions
- Female
- Humans
- Kidney
(pathology)
- Kidney Neoplasms
(diagnosis, secondary)
- Lymphoma
(diagnosis)
- Magnetic Resonance Imaging
(methods)
- Male
- Meglumine
(administration & dosage, analogs & derivatives)
- Middle Aged
- Organometallic Compounds
(administration & dosage)
|